The presence of minimal/measurable residual disease (MRD) before or after hematopoietic stem cell transplantation (HSCT) is known as a predictor of poor outcome in patients with acute myeloid (AML) or lymphoblastic (ALL) leukemia. When performed with multiparameter flow cytometry (MFC), assessment of residual leukemic cells after HSCT may be limited by therapy-induced shifts in the immunophenotype (e.g., loss of surface molecules used for therapeutic targeting). However, in such cases, questionable cells can be isolated and tested for hematopoietic chimerism to clarify their origin.

中文翻译：

---

通过流式细胞分选分离的可测量残留疾病疑似细胞的嵌合性评估作为异基因造血干细胞移植后急性白血病患者可测量残留疾病验证的可靠工具

造血干细胞移植 (HSCT) 之前或之后存在的最小/可测量残留病 (MRD) 被认为是急性髓性 (AML) 或淋巴细胞 (ALL) 白血病患者预后不良的预测因素。当使用多参数流式细胞术 (MFC) 进行时，HS​​CT 后残留白血病细胞的评估可能会受到治疗诱导的免疫表型变化的限制（例如，用于治疗靶向的表面分子的丢失）。然而，在这种情况下，可以分离有问题的细胞并测试造血嵌合体，以阐明它们的起源。